Methotrexate population PK in Mexican pediatric ALL
Indication: Acute lymphoblastic leukemia in pediatric patients receiving high-dose methotrexate
Interactive methotrexate population PK simulator for high-dose intravenous methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia. Methotrexate is an antifolate antimetabolite that inhibits dihydrofolate reductase (DHFR). Based on a published two-compartment population PK model for exposure assessment and dose optimization.
Drug Overview
Clinical Context
- Molecular Target
- Dihydrofolate reductase (DHFR)
- Drug Class
- Antifolate antimetabolite
- Therapeutic Area
- Oncology
- Indication
- Acute lymphoblastic leukemia in pediatric patients receiving high-dose methotrexate
- Route of Administration
- Intravenous infusion
Model Information
- Model Type
- Two-compartment population PK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Methotrexate population allows you to explore concentration-time profiles under different dosing scenarios. The underlying Two-compartment population PK model characterizes the pharmacokinetics of this antifolate antimetabolite following intravenous infusion administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Methotrexate population PK simulator?
This is a free, interactive pharmacokinetic simulator for Methotrexate population used in Acute lymphoblastic leukemia in pediatric patients receiving high-dose methotrexate. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Methotrexate population belong to?
Methotrexate population is classified as a Antifolate antimetabolite that targets Dihydrofolate reductase (DHFR). It is used in the Oncology therapeutic area.
What route of administration does this model simulate?
This simulator models Intravenous infusion administration of Methotrexate population. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Two-compartment population PK model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
G-CSF Effects in Carboplatin-Treated Cancer Patients
Chemotherapy-induced neutropenia
Population PKPD
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer
Tamoxifen
Hormone receptor-positive breast cancer adjuvant therapy
Pertuzumab
HER2-positive solid tumors
Serplulimab (HLX10) Population PK Simulator
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
5-FU A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses
Colorectal cancer and other gastrointestinal malignancies treated with infusional 5-FU regimens
Ready to Simulate?
Launch the Methotrexate population simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community